US Pharma MarketingASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Source: FiercePharma